These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22401771)

  • 1. CD70 expression patterns in renal cell carcinoma.
    Jilaveanu LB; Sznol J; Aziz SA; Duchen D; Kluger HM; Camp RL
    Hum Pathol; 2012 Sep; 43(9):1394-9. PubMed ID: 22401771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
    Huang RR; Chen Z; Kroeger N; Pantuck A; Said J; Kluger HM; Shuch B; Ye H
    Clin Genitourin Cancer; 2024 Apr; 22(2):347-353. PubMed ID: 38195301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
    Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
    Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
    Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
    Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
    Gibney GT; Aziz SA; Camp RL; Conrad P; Schwartz BE; Chen CR; Kelly WK; Kluger HM
    Ann Oncol; 2013 Feb; 24(2):343-349. PubMed ID: 23022995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
    Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.
    Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD70: a new tumor specific biomarker for renal cell carcinoma.
    Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
    J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.
    Spatz S; Tolkach Y; Jung K; Stephan C; Busch J; Ralla B; Rabien A; Feldmann G; Brossart P; Bundschuh RA; Ahmadzadehfar H; Essler M; Toma M; Müller SC; Ellinger J; Hauser S; Kristiansen G
    J Urol; 2018 Feb; 199(2):370-377. PubMed ID: 28827104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
    Chaux A; Schultz L; Albadine R; Hicks J; Kim JJ; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Hum Pathol; 2012 Dec; 43(12):2129-37. PubMed ID: 22542128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
    Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
    J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck.
    De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Ferdinande L; Rottey S
    Pathobiology; 2016; 83(6):327-33. PubMed ID: 27389010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
    Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
    Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
    Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E
    Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
    Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
    BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma.
    Arik D; Can C; Dündar E; Kabukçuoğlu S; Paşaoğlu Ö
    Pathol Oncol Res; 2017 Apr; 23(2):409-416. PubMed ID: 27738793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
    Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
    Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.